Investor Information
Stéphane Bette,
Co founder and Deputy CEO
Pierre Jérôme,
Co founder, CEO & Chairman
Dear Shareholders,
The Shareholder Meeting organized in May 2020 was an opportunity to review our 2019 results, to underline our latest progress and to share with you our perspectives on SpineGuard your company that we founded with the ambition, still intact, to make spine surgery safer and to exploit the full potential of DSG® (Dynamic Surgical Guidance) technology, unique in its ability to differentiate bony tissues in real-time and without using X-Rays.
Stock Information
Stock exchange information
- ISIN code: FR0011464452
- Stock Quote: ALSGD
- Number of shares: 23.473.000
- Sector: Medical technologies
- Principal Index: Alternext All-share
- Exchange: Euronext-Growth
- Place of listing: Euronext Paris (France)
- Eligibility to French PEA/SRD: Yes/No
- Eligibility French PEA-PME: Yes
Financial agenda
- 27 January 2021: 2020 Full-Year Sales
- 8 April 2021: 2020 Full-Year Results
- 15 April 2021: 2021 First-Quarter Sales
- 9 June 2021: Annual Shareholders Meeting
- 7 July 2021: 2021 First-Half Sales
- 15 Sep. 2021: 2021 First-Half Results
- 14 October 2021: 2021 Third-Quarter Sales
Analysts
- Biostrategic Research: Lionel Labourdette
Others
- Liquidity contract: Tradition Securities And Futures (TSAF)
- Auditors: Grant Thornton
- Listing Sponsor: Swiss Life Banque Privée
Shareholders structure
(November 30th, 2020)
Stock quotes
- To check the stock quote in real time, click here
For more information, do not hesitate to contact us
